Patent US4529603A successfully refreshed from Google Patents.
US4529603A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Pharmaceutical composition and method for treatment of psychomotor excitement
Assignee: Sumitomo Chemical Co Ltd
•
Filing: 1984-04-27
•
Granted: 1985-07-16
•
Expires: 2004-04-27
Abstract
Abstract A therapeutic agent for the treatment of psychomotor excitement containing as an active ingredient of L- or DL-erythro-3-(3,4-dihydroxyphenyl)-serine with or without a decarboxylase inhibitor.
Inventors
- 👤 Tadashi Mori
- 👤 Teruo Nakajima
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-30 14:47
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/185; A61K31/19; A61K31/195; A61P; A61P25/00; A61P25/18; A61P25/20
Claims Analysis
Total Claims: 18
Claim 1
Independent Claim
38 words
A method for the treatment of psychomotor excitement which comprises administration of an effective amount of erythro-3,4-dihydroxyphenylserine to a patient suffering from psychomotor excitement which is a mania or catatonic type of schizophrenia to suppress the psychomotor excitement.
Claim 2
Independent Claim
38 words
A method for the treatment of psychomotor excitement which comprises administration of an effective amount of erythro-3,4-dihydroxyphenylserine to a patient suffering from psychomotor excitement which is a mania or catatonic type of schizophrenia to suppress the psychomotor excitement.
Claim 3
Dependent Claim
20 words
A method for the treatment of psychomotor excitement according to claim 1, wherein the erythro-3,4-dihydroxyphenylserine is the DL-isomer or L-isomer.
Claim 4
Dependent Claim
28 words
A method for the treatment of psychomotor excitement according to claim 1, wherein there is included a decarboxylase inhibitor which is a member selected from benzerazide and carbidopa.
Claim 5
Dependent Claim
28 words
A method for the treatment of psychomotor excitement according to claim 1, wherein the erythro-3,4-dihydroxyphenylserine is orally administered in an amount of 0.1 to 4 g per day.
Claim 6
Dependent Claim
27 words
A method for the treatment of psychomotor excitement according to claim 1, wherein the erythro-3,4-dihydroxyphenylserine is intravenously administered in an amount of 0.1 to 2 per day.
Claim 7
Dependent Claim
32 words
A method for the treatment of psychomotor excitement according to claim 3, wherein the decarboxylase inhibitor is used in an amount of 0.0025 to 0.5 mole to 1 mole of the erythro-3,4-dihydroxyphenylserine.
Claim 8
Dependent Claim
33 words
A method according to claim 1 wherein there is present a decarboxylase inhibitor selected from the group consisting of benzerazide and carbidopa in an amount effective to enhance the effect of the erythro-3,4-dihydroxyphenylserine.
Claim 9
Dependent Claim
15 words
A method according to claim 1 carried out in the absence of a decarboxylase inhibitor.
Claim 10
Dependent Claim
51 words
An agent for the treatment of psychomotor excitement which is a mania or catatonic type of schizophrenia which comprises erythro-3,4-dihydroxyphenylserine in an amount to suppress the pyschonotor excitement and a decarboxylase inhibitor selected from the group consisting of benzerazide and carbidopa in an amount effective to enhance the effect of erythro-3,4-dihydroxyphenylserine.
Claim 11
Dependent Claim
51 words
An agent for the treatment of psychomotor excitement which is a mania or catatonic type of schizophrenia which comprises erythro-3,4-dihydroxyphenylserine in an amount to suppress the pyschonotor excitement and a decarboxylase inhibitor selected from the group consisting of benzerazide and carbidopa in an amount effective to enhance the effect of erythro-3,4-dihydroxyphenylserine.
Claim 12
Dependent Claim
19 words
An agent for the treatment of psychomotor excitement according to claim 9, wherein the erythro-3,4-dihydroxyphenylserine is DL-isomer or L-isomer.
Claim 13
Dependent Claim
32 words
An agent for the treatment of psychomotor excitement according to claim 9, wherein the decarbonylase inhibitor is included in an amount of 0.0025 to 0.5 mole to 1 mole of the erythro-3,4-dihydroxyphenylserine.
Claim 14
Dependent Claim
46 words
A therapeutic composition for use in the treatment of psychomotor excitement which is a mania or a catatonic type of schizophrenia which comprises an effective amount of L or DL-erythro-3,4-dihydroxyphenylserine as an active ingredient to suppress the psychomotor excitement and a pharmaceutically acceptable carrier or diluent.
Claim 15
Dependent Claim
46 words
A therapeutic composition for use in the treatment of psychomotor excitement which is a mania or a catatonic type of schizophrenia which comprises an effective amount of L or DL-erythro-3,4-dihydroxyphenylserine as an active ingredient to suppress the psychomotor excitement and a pharmaceutically acceptable carrier or diluent.
Claim 16
Dependent Claim
70 words
A therapeutic composition for use in the treatment of psychomotor excitement which is a mania or a catatonic type of schizophrenia which comprises an effective amount of L or DL-erthro-3,4-dihydroxyphenylserine to suppress the psychomotor excitement and an effective amount of a decarboxylase inhibitor selected from the group consisting of benzerazide and carbidopa as an active ingredient to enhance the effect of the erythro,3,4-dihydroxyphenylserine and a pharmaceutical acceptable carrier or diluent.
Claim 17
Dependent Claim
70 words
A therapeutic composition for use in the treatment of psychomotor excitement which is a mania or a catatonic type of schizophrenia which comprises an effective amount of L or DL-erthro-3,4-dihydroxyphenylserine to suppress the psychomotor excitement and an effective amount of a decarboxylase inhibitor selected from the group consisting of benzerazide and carbidopa as an active ingredient to enhance the effect of the erythro,3,4-dihydroxyphenylserine and a pharmaceutical acceptable carrier or diluent.
Claim 18
Dependent Claim
35 words
A therapeutic composition for use in the treatment of psychomotor excitement according to claim 13, wherein the decarboxylase inhibitor is included in an amount of 0.0025 to 0.5 mole to 1 mole of the erythro-3,4,-dihydroxyphenylserine.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1988-07-15 | 1989-01-14 | 1989-07-16 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1992-07-15 | 1993-01-14 | 1993-07-16 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1996-07-15 | 1997-01-14 | 1997-07-16 | $7700.00 | Window Closed / Lapsed |